RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase

Breast Cancer Research and Treatment

Volumn 146, Issue 3, 2014, Pages 515-523

  Hu, Hong ^a   Wang, Jun ^a   Gupta, Akash ^a   Shidfar, Ali ^a   Branstetter, Daniel ^b   Lee, Oukseub ^a   Ivancic, David ^a   Sullivan, Megan ^a   Chatterton, Robert T ^a   Dougall, William C ^b   Khan, Seema A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b AMGEN INC   (United States)

Author keywords

Luteal phase; Menstrual cycle; Progesterone; RANKL

Indexed keywords

MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PROGESTERONE; PROTEIN DIO2; PROTEIN MYBPC1; TUMOR PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; ESTRADIOL; IODIDE PEROXIDASE; IODOTHYRONINE DEIODINASE TYPE II; MYOSIN-BINDING PROTEIN C; TNFSF11 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUTEAL PHASE; MAJOR CLINICAL STUDY; MYBPC1 GENE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANKL GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR GENE; UPREGULATION; BIOSYNTHESIS; BLOOD; BREAST TUMOR; CARCINOGENESIS; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION REGULATION; GENETICS; MAMMARY GLAND; MENSTRUAL CYCLE; METABOLISM; MIDDLE AGED; PATHOLOGY; PRIMARY CELL CULTURE;

ADULT; AGED; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CARCINOGENESIS; CARRIER PROTEINS; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IODIDE PEROXIDASE; LUTEAL PHASE; MAMMARY GLANDS, HUMAN; MENSTRUAL CYCLE; MIDDLE AGED; PRIMARY CELL CULTURE; PROGESTERONE; RANK LIGAND;

EID: 84907598828     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3049-9     Document Type: Article

References (43)

1. Obr AE, Edwards DP (2012) The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 357:4-17
2. Schramek D, Sigl V, Penninger JM (2011) RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab 22:188-194
3. Fernandez-Valdivia R, Lydon JP (2012) From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol Cell Endocrinol 357:91-100
4. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Schneider P et al (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 107:2989-2994
5. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R et al (2010) RANK ligand mediates progestin induced mammary epithelial proliferation and carcinogenesis. Nature 468:103-107
6. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:98-102
7. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL et al (2010) Progesterone induces adult mammary stem cell expansion. Nature 465:803-807
8. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER et al (2010) Control of mammary stem cell function by steroid hormone signaling. Nature 465:798-802
9. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM et al (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:548-553
10. Beral V (2003) Breast cancer and hormone-replacement therapy in the million women study. Lancet 362:419-427
11. Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M (2006) Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer 118:1285-1291 (Pubitemid 43185619)
12. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684-1692
13. Ferguson DJ, Anderson TJ (1981) Morphological evaluation of cell turnover in relation to the menstrual cycle in the 'resting' human breast. Br J Cancer 44:177-181 (Pubitemid 11039573)
14. Ferguson DJ (1988) An ultrastructural study of mitosis and cytokinesis in normal 'resting' human breast. Cell Tissue Res 252:581-587
15. Anderson TJ, Battersby S, King RJ, McPherson K, Going JJ (1989) Oral contraceptive use influences resting breast proliferation. Hum Pathol 20:1139-1144 (Pubitemid 20034142)
16. Anderson TJ, Ferguson DJ, Raab GM (1982) Cell turnover in the 'resting' human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 46:376-382 (Pubitemid 12029884)
17. Going JJ, Anderson TJ, Battersby S, MacIntyre CC (1988) Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 130:193-204 (Pubitemid 18044847)
18. Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M et al (1988) The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 58:163-170
19. Bai M, Agnatis NJ, Kamina S, Demou A, Zagorianakou P, Katsaraki A et al (2001) In vivo cell kinetics in breast carcinogenesis. Breast Cancer Res 3:276-283 (Pubitemid 32631706)
20. Feuerhake F, Sigg W, Höfter EA, Unterberger P, Welsch U (2003) Cell proliferation, apoptosis, and expression of Bcl-2 and Bax in non-lactating human breast epithelium in relation to the menstrual cycle and reproductive history. Breast Cancer Res Treat 77:37-48 (Pubitemid 36182915)
21. Capuco AV, Ellis S, Wood DL, Akers RM, Garrett W (2002) Postnatal mammary ductal growth: three-dimensional imaging of cell proliferation, effects of estrogen treatment, and expression of steroid receptors in prepubertal calves. Tissue Cell 34:143-154
22. Clarke RB, Howell A, Potten CS, Anderson E (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987-4991 (Pubitemid 27498105)
23. Russo J, Ao X, Grill C, Russo IH (1999) Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53:217-227 (Pubitemid 29209891)
24. Seagroves TN, Lydon JP, Hovey RC, Vonderhaar BK, Rosen JM (2000) C/EBPbeta (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development. Mol Endocrinol 14:359-368 (Pubitemid 32260528)
25. Rajaram RD, Brisken C (2012) Paracrine signaling by progesterone. Mol Cell Endocrinol 357:80-90
26. Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI et al (2009) DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150:3318-3326
27. Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF et al (2013) Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 5(182):182ra55
28. Ramakrishnan R, Khan SA, Badve S (2002) Morphological changes in breast tissue with menstrual cycle. Mod Pathol 15:1348-1356 (Pubitemid 35463004)
29. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90:37-42 (Pubitemid 28078079)
30. Lee O, Helenowski IB, Chatterton RT, Jovanovic B, Khan SA (2012) Prediction of menopausal status from estrogen-related gene expression in benign breast tissue. Breast Cancer Res Treat 131:1067-1076
31. Wang J, Gupta A, Hu H, Chatterton RT, Clevenger CV, Khan SA (2013) Comment on "Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 5(215):215le4
32. Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H et al (2013) Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer. Cancer Prev Res 6:321-330
33. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S et al (2000) Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 92:1217-1227 (Pubitemid 30627730)
34. Chatterton RT, Khan SA, Heinz R, Ivancic D, Lee O (2010) Patterns of sex steroid hormones in nipple aspirate fluid during the menstrual cycle and after menopause in relation to serum concentrations. Cancer Epidemiol Biomark Prev 19:275-279
35. Burger HG, Dudley EC, Robertson DM, Dennerstein L (2002) Hormonal changes in the menopause transition. Recent Prog Horm Res 57:257-275
36. Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P, Stricker R (2006) Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin Chem Lab Med 44:883-887
37. Wood CE, Branstetter D, Jacob AP, Cline JM, Register TC, Rohrbach K et al (2013) Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res 15:R62
38. Brisken C (2013) Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer 13:385-396
39. Jankowitz RC, McGuire KP, Davidson NE (2013) Optimal systemic therapy for premenopausal women with hormone receptorpositive breast cancer. Breast 22:S165-S170
40. Casula S, Bianco AC (2012) Thyroid hormone deiodinases and cancer. Front Endocrinol 3:74
41. Debski MG, Pachucki J, Ambroziak M, Olszewski W, Bar-Andziak E (2007) Human breast cancer tissue expresses high level of type 1 5-deiodinase. Thyroid 17:3-10 (Pubitemid 46214716)
42. Dentice M, Luongo C, Huang S, Ambrosio R, Elefante A, Mirebeau-Prunier D et al (2007) Sonic hedgehog-induced type3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes. Proc Natl Acad Sci USA 104:14466-14471 (Pubitemid 350003284)
43. Chen Z, Zhao TJ, Li J, Gao YS, Meng FG, Yan YB et al (2011) Slow skeletal muscle myosin-binding protein-C (MyBPC1) mediates recruitment of muscle-type creatine kinase (CK) to myosin. Biochem J 436:437-445